drugset / Trial / NCT00987454

Summary

This study seeks to determine if erythropoietin alpha (EPO) administered to adult critical care patients with moderate or severe traumatic brain injury improves neurological function assessed at six months after injury.

Timeline

Start
2010-05
Primary completion
2015-05
Completion
2015-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous